History of Untreated Psychosis: the Impact on Prognosis of Paranoid Schizophrenia. Case Report
https://doi.org/10.30629/2618-6667-2024-22-6-72-81
Abstract
Background: psychiatrists often face difficulties in selecting appropriate psychopharmacological treatments when patients with Schizophrenia spectrum disorders have been without adequate antipsychotic medication for a long period. This can lead to unforeseen complications and difficulties in case managing. The relevance of this issue is highlighted by numerous clinical and statistical studies that demonstrate the high prevalence of these disorders among psychiatric hospital patients. Additionally, the course of the illness can vary depending on untreated period duration, which has important scientific and practical implications for long-term treatment outcomes, therapy effectiveness, and the timing and quality of remissions. The aim: using a case report as an example to evaluate the impact of long-term nontreatment, we will look at the degree of improvement in psychotic symptoms and the prognosis for paranoid schizophrenia after a long period of untreated psychosis. Patient and Methods: clinicalpsychopathological and clinical-dynamic methods were used to study the clinical manifestations in a patient with paranoid syndrome and deficit symptoms, within the context of a continuous form of paranoid schizophrenia, against the background of a prolonged period of untreated psychosis. Results: the presented clinical case highlights the issue of a poor prognosis after a long period of untreated psychosis. The treatment plan consisted of a combination of traditional first-generation antipsychotics and clozapine, which has been shown to be highly effective and safe in treating paraphrenia in schizophrenia. Conclusion: the clinical observation in question emphasized the significance of timely and appropriate initiation of treatment at the onset of first psychotic episode. Long period of untreated psychosis have been shown to negatively impact the effectiveness of psychopharmacological therapy and the overall outcome of the illness.
About the Authors
V. А. Chinarev
South Ural State Medical University of Russian Federation Ministry of Health; GBUZ OKSPNB No. 1
Russian Federation
Russian Federation
Vitaly A. Chinarev, Assistant Professor, Department of Psychiatry; Head of Psychiatric unit of the rst episode
Chelyabinsk
E. V. Malinina
South Ural State Medical University of Russian Federation Ministry of Health
Russian Federation
Russian Federation
Elena V. Malinina, Dr. Sci. (Med.), Professor, Head of Psychiatry Department
Chelyabinsk
M. D. Obukhova
South Ural State Medical University of Russian Federation Ministry of Health
Russian Federation
Russian Federation
Maria D. Obukhova, student
Chelyabinsk
References
1. Williams R, Ostinelli EG, Agorinya J, Minichino A, De Crescenzo F, Maughan D, Puntis S, Cliffe C, Kurtulmus A, Lennox BR, Cipriani A. Comparing interventions for early psychosis: a systematic review and component network meta-analysis. EClinicalMedicine. 2024 Mar 14;70:102537. doi: 10.1016/j.eclinm.2024.102537. PMID: 38516103; PMCID: PMC10955207.
2. Stolyarov SA. Kliniko-dinamicheskiye kharakteristiki terapevticheskikh remissiy posle ostrykh paranoidnykh psikhozov u bol’nykh shizofreniyey na lechenii neyroleptikami raznykh pokoleniy. Psychiatry (Moscow) (Psikhiatriya). 2020;18(2):21–31. (In Russ.). doi: 10.30629/2618-6667-2020-18-2-21-31
3. Petrova NN, Tsyrenova KA. Clinical and Therapeutic Factors Affecting the Social Adaptation of Patients with Schizophrenia. Psychiatry (Moscow) (Psikhiatriya). 2021;19(4):26–33. (In Russ.). doi: 10.30629/2618-6667-2021-19-4-26-33
4. Kesteven WB. On the early phases of mental disorders, and their treatment. Part 1. J Ment Sci. 1881:27;353–359.
5. Napier Pearn OP. Psychoses in the Expeditionary Forces. Journal of Mental Science. 1919;65(269):101–108. doi: 10.1192/bjp.65.269.101
6. Souaiby L, Gaillard R, Krebs MO. Durée de psychose non traitée: état des lieux et analyse critique [Duration of untreated psychosis: A state-of-theart review and critical analysis]. Encephale. 2016 Aug;42(4):361–366. French. doi: 10.1016/j.encep.2015.09.007. Epub 2016 May 6. PMID: 27161262
7. Nkire N, Kinsella A, Russell V, Waddington JL. Duration of the psychosis prodrome and its relationship to duration of untreated psychosis across all 12 DSM-IV psychotic diagnoses: Evidence for a trans-diagnostic process associated with resilience. Eur Neuropsychopharmacol. 2024 Mar;80:5–13. doi: 10.1016/j. euroneuro.2023.12.005. Epub 2023 Dec 20. PMID: 38128335.
8. Ajnakina O, Rodriguez V, Quattrone D, di Forti M, Vassos E, Arango C, Berardi D, Bernardo M, Bobes J, de Haan L, Del-Ben CM, Gayer-Anderson C, Jongsma HE, Lasalvia A, Tosato S, Llorca PM, Menezes PR, Rutten BP, Santos JL, Sanjuán J, Selten JP, Szöke A, Tarricone I, D’Andrea G, Richards A, Tortelli A, Velthorst E, Jones PB, Arrojo Romero M, La Cascia C, Kirkbride JB, van Os J, O’Donovan M, Murray RM; EU-GEI WP2 Group. Duration of Untreated Psychosis in First-Episode Psychosis is not Associated with Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study. Schizophr Bull. 2021 Oct 21;47(6):1653–1662. doi: 10.1093/schbul/sbab055. PMID: 33963865; PMCID: PMC8562562.
9. Philip BV, Cherian A, Shankar R, Rajaram. Severity of disability in persons with schizophrenia and its sociodemographic and illness correlates. Indian Journal of Social Psychiatry. 2020;36(1):80–86. doi: 10.4103/ ijsp.ijsp_3_19
10. Cavalcante DA, Coutinho LS, Ortiz BB, Noto MN, Cordeiro Q, Ota VK, Belangeiro SI, Bressan RA, Gadelha A, Noto C. Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve rst-episode psychosis. Early Interv Psychiatry. 2020 Dec;14(6):677–683. doi: 10.1111/ eip.12889. Epub 2019 Oct 21. PMID: 31637865.
11. Friis S, Melle I, Johannessen JO, Røssberg JI, Barder HE, Evensen JH, Haahr U, Ten Velden Hegelstad W, Joa I, Langeveld J, Larsen TK, Opjordsmoen S, Rund BR, Simonsen E, Vaglum PW, McGlashan TH. Early Predictors of Ten-Year Course in First-Episode Psychosis. Psychiatr Serv. 2016 Apr 1;67(4):438–443. doi: 10.1176/appi.ps 201400558. Epub 2015 Nov 16. PMID: 26567932.
12. Zhang T, Cui H, Wei Y, Tang X, Xu L, Hu Y, Tang Y, Liu H, Wang Z, Chen T, Li C, Wang J. Duration of Untreated Prodromal Psychosis and Cognitive Impairments. JAMA Netw Open. 2024 Jan 2;7(1):e2353426. doi: 10.1001/jamanetworkopen.2023.53426. PMID: 38277145; PMCID: PMC10818213.
13. Smart SE, Agbedjro D, Pardiñas AF, Ajnakina O, Alameda L, Andreassen OA, Barnes TRE, Berardi D, Camporesi S, Cleusix M, Conus P, Crespo-Facorro B, D’Andrea G, Demjaha A, Di Forti M, Do K, Doody G, Eap CB, Ferchiou A, Guidi L, Homman L, Jenni R, Joyce E, Kassoumeri L, Lastrina O, Melle I, Morgan C, O’Neill FA, Pignon B, Restellini R, Richard JR, Simonsen C, Španiel F, Szöke A, Tarricone I, Tortelli A, Üçok A, Vázquez-Bourgon J, Murray RM, Walters JTR, Stahl D, MacCabe JH. Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium. Schizophr Res. 2022 Dec;250:1–9. doi: 10.1016/j.schres.2022.09.009. Epub 2022 Oct 12. PMID: 36242784; PMCID: PMC9834064.
14. Zaytseva YuS. Znacheniye pokazatelya “dlitelnost nelechennogo psikhoza” pri pervom psikhoticheskom epizode shizofrenii. Social and Clinical Psychiatry. 2007;17(1):72–79. (In Russ.).
15. Shashkova NG, Gazha AK. The rst psychotic episode: peculiarities of providing mental health services to patients under modern conditions. Social and Clinical Psychiatry. 2020;30(2):80–90. (In Russ.).
16. Agarwal SM, Dissanayake J, Agid O, Bowie C, Brierley N, Chintoh A, De Luca V, Diaconescu A, Gerretsen P, Graff-Guerrero A, Hawco C, Herman Y, Hill S, Hum K, Husain MO, Kennedy JL, Kiang M, Kidd S, Kozloff N, Maslej M, Mueller DJ, Naeem F, Neufeld N, Remington G, Rotenberg M, Selby P, Siddiqui I, Szacun-Shimizu K, Tiwari AK, Thirunavukkarasu S, Wang W, Yu J, Zai CC, Zipursky R, Hahn M, Foussias G. Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol. PLoS One. 2023 Sep 21;18(9):e0288354. doi: 10.1371/ journal.pone.0288354. PMID: 37733693; PMCID: PMC10513234.
17. Karyakina MV, Rychkova OV, Shmukler AB. Cognitive impairments in schizophrenia in foreign studies: single function decits or group of syndromes? Journal of Modern Foreign Psychology. 2021;10(2):8–19. (In Russ.).
18. Grifths SL, Bogatsu T, Longhi M, Butler E, Alexander B, Bandawar M, Everard L, Jones PB, Fowler D, Hodgekins J, Amos T, Freemantle N, McCrone P, Singh SP, Birchwood M, Upthegrove R. Five-year illness trajectories across racial groups in the UK following a first episode psychosis. Soc Psychiatry Psychiatr Epidemiol. 2023 Apr;58(4):569–579. doi: 10.1007/s00127-023-02428-w. Epub 2023 Jan 30. PMID: 36717434; PMCID: PMC10066114.
19. Chinarev VA, Malinina EV. The rst psychotic episode: clinical and diagnostic aspects and therapeutic approaches. Doctor.Ru. 2024;23(7):102–112. (In Russ.). doi: 10.31550/1727-2378-2024-23-7-102-112
20. Danilov DS. Аntipsychotic drug therapy of continuous paranoid schizophrenia (a comparative study of the efcacy of clozapine, risperidone, olanzapine and high potency traditional neuroleptics). Rossiyskiy psikhiatricheskiy zhurnal = Russian_Journal_of_Psychiatry. 2009;(3):71–80. (In Russ.).
21. Subbotskaya NV. Acute paraphrenic states in the clinical presentation of attack-like schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(11–2):49–56. (In Russ.). doi: 10.17116/ jnevro201511511249-56.
22. Stoychev KR, Ivanov K, Kozhukharov KV, Khrusafov DS, Aleksandrova M, B’rkashka DA. Antypsychotics in schizophrenia treatment (literature review). Human. Sport. Medicine. 2016;16(3):25–36. (In Russ.).
23. Podsevatkin VG, Shubin DYu, Kolmykov VA, Govsh EV, Razgadova EA. Sravnitelnaya kharakteristika sovremennykh farmakologicheskikh podkhodov k lecheniyu shizofrenii. In: XLIX Ogarevskie chteniia. Materialy nauchnoi konferentsii: v 3 ch. Saransk: Izdatel’stvo Natsional’nogo issledovatel’skogo Mordovskogo gosudarstvennogo universiteta im. N.P. Ogareva. 2021;(1):220–225. (In Russ.).
24. Salazar de Pablo G, Guinart D, Correll CU. What are the physical and mental health implications of duration of untreated psychosis? Eur Psychiatry. 2021 Mar 29;64(1):e46. doi: 10.1192/j.eurpsy.2021.22. PMID: 33775268; PMCID: PMC8316447.
25. Abramov VA, Likholetova OI, Putyatin GG. Clinical analysis of initial prodrome of schizophrenia in temporal,gender and age aspects. The Journal of Psychiatry and Medical Psychology. 2012;2(29):15–29. (In Russ.).
26. Berendsen S, Van HL, van der Paardt JW, de Peuter OR, van Bruggen M, Nusselder H, Jalink M, Peen J, Dekker JJM, de Haan L. Exploration of symptom dimensions and duration of untreated psychosis within a staging model of schizophrenia spectrum disorders. Early Interv Psychiatry. 2021 Jun;15(3):669–675. doi: 10.1111/eip.13006. Epub 2020 Jun 17. PMID: 32558322; PMCID: PMC8246761.
27. Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014 Aug;205(2):88–94. doi: 10.1192/bjp.bp.113.127753. Epub 2014 Aug 1. PMID: 25252316.
Review
For citations:
Chinarev V.А., Malinina E.V., Obukhova M.D. History of Untreated Psychosis: the Impact on Prognosis of Paranoid Schizophrenia. Case Report. Psychiatry (Moscow) (Psikhiatriya). 2024;22(6):72-81. (In Russ.) https://doi.org/10.30629/2618-6667-2024-22-6-72-81
Views:
2496
Email this article 
